Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
<anakinra, effect, TNF-blocking agent>, <interleukin-1 antagonist, effect, TNF-blocking agent>